5//SEC Filing
IMCOR PHARMACEUTICAL CO 5
Accession 0001181431-05-010927
CIK 0000761237operating
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 2:28 PM ET
Size
12.9 KB
Accession
0001181431-05-010927
Insider Transaction Report
Form 5
FLEMING JONATHAN
Director10% Owner
Transactions
- Award
Common Stock
2004-09-28$0.13/sh+338,461$44,000→ 43,928,168 total(indirect: By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.) - Award
Common Stock
2004-10-28$0.06/sh+733,334$44,000→ 44,661,502 total(indirect: By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.) - Award
Common Stock
2004-11-28$0.20/sh+220,000$44,000→ 44,881,502 total(indirect: By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.) - Award
Common Stock
2004-12-28$0.55/sh+80,000$44,000→ 44,961,502 total(indirect: By Oxford Bioscience Partners IV L.P. and MRNA Fund II L.P.)
Footnotes (11)
- [F1]Pursuant to Section 2(c) of the Company's Registration Rights Agreements dated April 19, 2004 and June 30, 2004, the Issuer issued such shares as liquidated damages in respect of the delayed effectiveness of the Issuer's resale registration statement for the applicable period.
- [F10]Of the 80,000 shares issued on December 28, 2004, 79,205 shares were issued to Oxford and 795 shares were issued to MRNA.
- [F11]Of the 44,961,502 shares held on December 28, 2004, 44,514,866 shares were held by Oxford and 446,636 shares were held by MRNA.
- [F2]Jonathan Fleming is the general partner of OBP Management IV L.P., which is the general partner of both Oxford Bioscience Partners IV L.P. ("Oxford") and MRNA Fund II L.P. ("MRNA"). As such, Mr. Fleming and OBP Management IV L.P. disclaim beneficial ownership except to the extent of their pecuniary interests.
- [F3]Of the 338,461 shares issued on September 28, 2004, 335,099 shares were issued to Oxford and 3,362 shares were issued to MRNA.
- [F4]Prior to receiving the shares in respect of the late effectiveness of the resale registration statement, each of Oxford and MRNA adjusted the holdings reported on July 2, 2004 to reflect a decrease of 176,684 shares by Oxford, thus resulting in a revised opening balance for this Form 5 of 43,156,698 for Oxford, and an increase of 31,622 shares by MRNA, thus resulting in a revised opening balance for this Form 5 of 433,009 for MRNA, to correct a miscalculation of shares issued in connection with the prior conversion of interest payments.
- [F5]Of the 43,928,168 shares held on September 28, 2004, 43,491,797 shares were held by Oxford and 436,371 shares were held by MRNA.
- [F6]Of the 733,334 shares issued on October 28, 2004, 726,049 shares were issued to Oxford and 7,285 shares were issued to MRNA.
- [F7]Of the 44,661,502 shares held October 28, 2004, 44,217,846 shares were held by Oxford and 443,656 shares were held by MRNA.
- [F8]Of the 220,000 shares issued on November 28, 2004, 217,815 shares were issued to Oxford and 2,185 shares were issued to MRNA.
- [F9]Of the 44,881,502 shares held on November 28, 2004, 44,435,661 shares were held by Oxford and 445,841 shares were held by MRNA.
Documents
Issuer
IMCOR PHARMACEUTICAL CO
CIK 0000761237
Entity typeoperating
IncorporatedNV
Related Parties
1- filerCIK 0000761237
Filing Metadata
- Form type
- 5
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 2:28 PM ET
- Size
- 12.9 KB